Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. India
  4. NSE India Stock Exchange
  5. Cadila Healthcare Limited
  6. News
  7. Summary
    CADILAHC   INE010B01027

CADILA HEALTHCARE LIMITED

(CADILAHC)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsOther languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

Cadila Healthcare : J&J says in talks with Indian govt for trial of single-dose vaccine

04/09/2021 | 02:10am EDT

BENGALURU, April 9 (Reuters) - Johnson & Johnson is in talks with India's government to begin a clinical trial of its single-dose COVID-19 vaccine in the country, the company said on Friday.

The U.S. drugs and healthcare giant's vaccine is currently approved for use in the United States, the European Union and other nations including Thailand and South Africa.

The news comes as some parts of India face a shortage of vaccine supplies just as the country of 1.3 billion battles a second wave of COVID-19 infections. India's government, however, has said there is no shortage of shots.

The Indian Express newspaper reported earlier on Friday that J&J had sent a letter to India's Central Drugs Standard Control Organisation (CDSCO) saying it would "very shortly apply for permission to conduct clinical bridging trials in India".

The CDSCO did not immediately respond to Reuters request for comment.

"We are in discussions with the (government) with the objective of starting a bridging clinical study of our Janssen COVID-19 vaccine candidate in India, subject to local regulatory approvals," a local J&J representative said via email.

A bridging study tests the safety and immunogenicity of a vaccine, and India has indicated that any vaccine maker must conduct such a trial for a shot to be considered for its immunisation programme.

Separately, J&J has a deal with Indian firm Biological E Ltd to contract-manufacture its vaccine.

India currently has two approved vaccines in use, one developed by Oxford University and AstraZeneca and the other, a shot from local player Bharat Biotech.

There are other vaccine candidates in trials in India including Russia's Sputnik-V and a shot developed by Cadila Healthcare Ltd.

COVID-19 infections in India rose by a record number for a third straight day on Friday, increasing by more than 130,000, while daily deaths hit their highest in five months. (Reporting by Sachin Ravikumar and Anuron Kumar Mitra in Bengaluru; Editing by Shounak Dasgupta and Shailesh Kuber)


ę Reuters 2021
Stocks mentioned in the article
ChangeLast1st jan.
ASTRAZENECA PLC -0.23% 7717 Delayed Quote.5.61%
CADILA HEALTHCARE LIMITED 3.45% 624 Delayed Quote.26.52%
All news about CADILA HEALTHCARE LIMITED
07:12aCADILA HEALTHCAREá : Zydus Wellness' consolidated Q4 Net Profit up by 92.7% at R..
PU
05/05MARKET CHATTER : Cadila Healthcare May Apply for Approval for COVID-19 Vaccine i..
MT
05/03Glenmark, Alembic, Ipca Invest in ABCD Technologies; Stakes of Dr. Reddy's, O..
MT
05/01CADILA HEALTHCAREá : SE Intimation ABCD Technologies LLP
PU
04/26CADILA HEALTHCAREá : Zydus Cadila receives final approval from USFDA for Propafe..
AQ
04/26CADILA HEALTHCAREá : Zydus receives Emergency Use Approval from DCGI for the use..
AQ
04/26CADILA HEALTHCAREá : Secures Indian Drug Regulator's Approval for COVID-19 Drug ..
MT
04/23FACTBOX-Latest on the worldwide spread of the coronavirus
RE
04/23India's Cadila Healthcare starts producing COVID-19 vaccine candidate
RE
04/23CADILA HEALTHCAREá : Zydus receives Emergency Use Approval from DCGI for the use..
PU
More news
Financials
Sales 2021 151 B 2 057 M 2 057 M
Net income 2021 19 102 M 260 M 260 M
Net Debt 2021 49 114 M 669 M 669 M
P/E ratio 2021 32,7x
Yield 2021 0,58%
Capitalization 639 B 8 720 M 8 706 M
EV / Sales 2021 4,56x
EV / Sales 2022 4,15x
Nbr of Employees 25 000
Free-Float 25,0%
Chart CADILA HEALTHCARE LIMITED
Duration : Period :
Cadila Healthcare Limited Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends CADILA HEALTHCARE LIMITED
Short TermMid-TermLong Term
TrendsBullishBullishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 27
Average target price 497,46 INR
Last Close Price 624,00 INR
Spread / Highest target -5,45%
Spread / Average Target -20,3%
Spread / Lowest Target -45,5%
EPS Revisions
Managers and Directors
NameTitle
Sharvil Pankajbhai Patel Managing Director & Executive Director
Nitin Dalsukhrai Parekh Chief Financial Officer
Pankaj Ramanbhai Patel Non-Executive Chairman
Ganesh Narayan Nayak Chief Operating Officer & Executive Director
Dhaval N. Soni Secretary & Compliance Officer